Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation – a cohort study from Sweden using propensity score analyses

Table 3 Cox regression models with total mortality as outcome for patients for patients aged ≥45 years with diagnoses of AF and diabetes mellitus ( n = 2,413) attending the 75 PHCCs between January 1^st2001 and December 31^st2007, stratified by age: 45–79 years (n = 1,704) and 80–104 years (n = 709)

	Patients aged <80 years	Patients aged ≥80 years	All patients
	Full model	Full model	Full model
	HR (95% CI)	HR (95% CI)	HR (95% CI)
Antithrombotic drugs
Antiplatelets vs. no treatment	0.86 (0.43-1.72)	0.47 (0.26-0.87)	0.70 (0.45-1.09)
Anticoagulants vs. no treatment	0.40 (0.17-0.91)	0.49 (0.24-1.00)	0.45 (0.26-0.77)
Anticoagulants vs. antiplatelets	0.44 (0.25-0.78)	1.02 (0.60-1.73)	0.62 (0.42-0.92)
Digitalis	0.81 (0.54-1.23)	0.90 (0.60-1.35)	0.83 (0.62-1.11)
Loop diuretics	2.42 (1.36-4.33)	1.02 (0.60-1.73)	1.55 (1.06-2.28)
Thiazides	0.98 (0.59-1.63)	0.89 (0.55-1.44)	0.93 (0.66-1.32)
Aldosterone antagonists	1.20 (0.76-1.88)	1.22 (0.79-1.88)	1.29 (0.94-1.77)
Beta blockers	0.62 (0.40-0.97)	0.73 (0.49-1.10)	0.67 (0.49-0.90)
RAS-blocking agents	1.08 (0.65-1.78)	1.23 (0.79-1.93)	1.16 (0.83-1.62)
Calcium receptor-blocking agents	1.06 (0.69-1.63)	1.20 (0.77-1.87)	1.10 (0.81-1.49)
Statins	0.45 (0.29-0.71)	0.77 (0.47-1.26)	0.56 (0.40-0.78)

Full model is adjusted for a propensity score comprising sex, age group, co-morbidities, educational level, marital status and for all pharmacotherapies. HRs and 95% CIs are shown. Statistically significant HRs are highlighted in bold.